TENX - Tenax Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1000
-0.0900 (-7.56%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.1900
Open1.1300
Bid0.00 x 900
Ask1.34 x 1000
Day's Range1.0500 - 1.1300
52 Week Range1.0300 - 12.6300
Volume233,323
Avg. Volume315,482
Market Cap1.612M
Beta (3Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire7 days ago

    Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering

    Tenax Therapeutics, Inc. (TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the closing of an underwritten offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Tenax. The offering was comprised of 5,181,346 units, priced at an offering price of $1.93 per unit, with each unit consisting of one share of Series A convertible preferred stock, having a conversion price of $1.93, a two-year warrant to purchase one share of common stock with an exercise price of $1.93 per share, and a five-year warrant to purchase one share of common stock with an exercise price of $1.93 per share.

  • Business Wire11 days ago

    Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

    Tenax Therapeutics, Inc. (TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the pricing of an underwritten offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Tenax. The offering is comprised of 5,181,346 units, priced at an offering price of $1.93 per unit, with each unit consisting of one share of Series A convertible preferred stock, having a conversion price of $1.93, a two-year warrant to purchase one share of common stock with an exercise price of $1.93 per share, and a five-year warrant to purchase one share of common stock with an exercise price of $1.93 per share.

  • Business Wire29 days ago

    Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that Stanford University School of Medicine has been activated as the first clinical research site for the Company’s Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study is also known as the H-E-L-P Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF) and is expected to enroll a total of 36 PH-HFpEF patients at up to approximately 12-15 major research institutions across the US. Anthony DiTonno, CEO of Tenax Therapeutics, Inc., stated, “We are very excited to have activated our first site for the HELP trial.

  • Business Wire3 months ago

    Tenax Therapeutics to Present at Upcoming Investor Conferences

    For more information, please visit the company website at www.tenaxthera.com. Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market.

  • Business Wire4 months ago

    Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that the Company will participate in the H.C. Wainwright 20th Annual Global Investment Conference, which takes place September 4-6, in New York. Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company has a world-class scientific team including recognized global experts in pulmonary hypertension.

  • Business Wire4 months ago

    Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients

    Tenax Therapeutics, Inc. (TENX) today announced the results of a new study titled "Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment: A Randomized Double‐Blind Controlled Trial” were published in the August 21, 2018 issue of the Journal of the American Heart Association (https://www.ahajournals.org/doi/full/10.1161/JAHA.117.008455). The results indicate that levosimendan offers unique renal protective benefits to patients who have heart failure and coexisting impairment of their kidney function.

  • Business Wire6 months ago

    Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the Company has selected board member Anthony A. DiTonno to be its next Chief Executive Officer, effective June 1, 2018. Michael Jebsen, Tenax’s current Interim Chief Executive Officer and Chief Financial Officer, will remain serving as Tenax’s Chief Financial Officer.

  • Business Wire7 months ago

    Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the registration of their Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) on ClinicalTrials.gov. The Phase 2 PH-HFpEF study is a multi-center, double blind, randomized, placebo-controlled clinical trial that is testing the hypothesis that chronic, intermittent doses of levosimendan will significantly improve hemodynamic measures of exercise performance in patients suffering from Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

  • ACCESSWIRE8 months ago

    This $3 Medical Device Stock be Worth $9-14 with Impending Product Launch

    - Cardiology interventions and diagnostics are a big market, and the new field of remote monitoring, for arrhythmias and heart trouble, is a rapidly expanding component. Better remote monitoring technology ...

  • Business Wire8 months ago

    Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients

    Tenax Therapeutics, Inc.  , a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the results of its pre-Investigational New Drug meeting with the United States Food & Drug Administration , where the FDA addressed the Company’s questions and provided guidance on its upcoming Phase 2 clinical trial in the use of levosimendan ...

  • Business Wire9 months ago

    Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

    Tenax Therapeutics, Inc.  , a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced that it has regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550 .

  • ACCESSWIRE10 months ago

    Today’s Research Reports on Stocks to Watch: Novavax and Tenax Therapeutics

    NEW YORK, NY / ACCESSWIRE / March 2, 2018 / Novavax shares soared higher on Thursday after the company revealed positive data from a trial on its flu vaccine NanoFlu. Shares of Tenax Therapuetics also ...

  • Business Wire10 months ago

    Tenax Therapeutics Announces New Scientific Publication of Preclinical Data Provides Additional Evidence of Levosimendan Treatment Effects in Pulmonary Hypertension

    Tenax Therapeutics, Inc.  today announced the publication of a positive preclinical study of levosimendan conducted by Hansen et al in the March 1, 2018, issue of Pulmonary Circulation.

  • Business Wire10 months ago

    Tenax Therapeutics Announces Reverse Stock Split

    Tenax Therapeutics, Inc.  , a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20.

  • Business Wire10 months ago

    World-Recognized Experts Join Tenax Therapeutics’ Scientific Advisory Board to Guide New Phase 2 Study

    Tenax Therapeutics, Inc. a leading specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the appointment of three internationally recognized medical experts in the fields of pulmonary hypertension and heart failure with preserved ejection fraction to its Scientific Advisory Board for the company’s planned Phase 2 clinical ...

  • Business Wire11 months ago

    Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies

    Tenax Therapeutics, Inc.  today announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction .